Clinical Trial Update: Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela

View source ↗

Summary

This update describes the local adaptation of a cost-effectiveness model for apixaban in non-valvular atrial fibrillation for Venezuela, with the study status m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Valvular Atrial Fibrillation | Status: COMPLETED